TLR4 and melanoma: Our data showed that icariside II treatment could effectively inhibit paclitaxel-induced activation of TLR4-MyD88-ERK signaling pathway in human melanoma A375 cells, which is proposed to be a novel target for reversing chemoresistance to paclitaxel.